AlphAIAlphAI — Financial news for AI agents
investing.comOCT 132 min read$JNJ

Why is Johnson & Johnson stock sliding today?

Johnson & Johnson (JNJ) stock fell 2.5% in pre-market trading despite a solid Q3 2026 earnings report. Adjusted EPS beat estimates at $2.59, with revenue of $25.4B, up 5.9% YoY. GAAP EPS dropped 95.9% to $210M due to one-time charges. The company raised its full-year guidance to $11.05–$11.15 adjusted EPS. Medical device sales grew slowly, while pharmaceutical sales rose 7.7%. The stock traded below moving averages, and analysts revised EPS estimates downward.

Original reporting
investing.com
Published Oct 13, 2026, 11:28 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 11:57 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$JNJ
Bearish
high confidence
Mentioned
$JNJ
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$JNJBearishHigh
01

Why it matters

Earnings beat on adjusted metrics is muted by a GAAP loss and a $5.5 B talc settlement, leading to a modest pre‑market decline.

02

Market read

The earnings release provides fresh data that moves JNJ stock and may influence peer healthcare stocks.

03

What to watch

Potential spin‑off of the orthopedics business and long‑term demand for oncology drugs may provide upside.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Johnson & Johnson's Q3 earnings were released amid a broader chip sell‑off and AI‑related market concerns.

Company-level read

Ticker impact

$JNJBearishHigh confidence
Context

Johnson & Johnson reported Q3 2026 earnings with adjusted EPS beat, GAAP EPS miss due to a special charge, raised full-year guidance, and the stock slid 2.5% in pre‑open trading.

Expected impact

downward pressure as investors price in the GAAP miss and settlement uncertainty

Evidence & confidence

Pre‑market slide of 2.5% reflects market reaction to the GAAP earnings miss and legal charge despite guidance raise.

Market effects

Sector

Healthcare sector may see broader weakness as investors scrutinize medical device earnings and legal exposures.

Regional

U.S. large‑cap healthcare stocks could face modest sell pressure in early trading.

Global

Limited to U.S. markets; no immediate global macro impact.

Counterpoint

What could challenge this read

The raised full‑year guidance and strong pharma growth could support a rebound if the market overreacts to the GAAP miss.

Key entities

  • company
    Johnson & Johnson

    U.S. healthcare conglomerate reporting Q3 2026 results.

  • company
    Firefly Bio, Inc.

    Acquisition target mentioned in the earnings release.

  • company
    Sail Biomedicines

    Strategic collaboration partner mentioned in the earnings release.

Read at source← All news

Also covered by

4 outlets

Related articles

OCT 13
$JNJHighAI 9/10

Johnson & Johnson reports Q3 2026 results, raises 2026 guidance

JOHNSON & JOHNSON (JNJ) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Media contact: media-relations@its.jnj.com Investor contact: investor-relations@its.jnj.com For immediate release Johnson & Johnson reports Q3 2026 results, raises 2026 guidance • 2026 Third-Quarter reported sales growth of 5.9% to $25.4 Billion with operational grow

SEC EDGAR 8-K6 min
OCT 13
$JNJHighAI 9/10

Johnson & Johnson (JNJ) Raises 2026 Sales and EPS Guidance After

Johnson & Johnson (JNJ) reported Q3 non-GAAP EPS of $2.59, beating estimates by $0.06. The company raised its 2026 sales forecast to $101.2B and adjusted EPS guidance to $11.10. Shares gained 1% in after-hours trading. JNJ offers a 1.95% dividend yield with a 55% payout ratio and a 4.9% 3-year dividend growth rate. The company's GF Score™ is 83/100, reflecting strong financial health and growth prospects. Insider activity shows significant net selling over the past 12 months.

gurufocus.com2 min